CDKN2D Antibodies

Cyclin-dependent kinase 4 inhibitor D (CDKN2D)

Interacts strongly with CDK4 and CDK6 and inhibits them.

.

Gene Information

Human
Gene Name:	CDKN2D
Uniprot:	P55273
Entrez:	1032

Family

Belongs to:
CDKN2 cyclin-dependent kinase inhibitor family

Alternative Names

CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent kinase 4 inhibitor D p19; cyclin-dependent kinase 4 inhibitor D; cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4); inhibitor of cyclin-dependent kinase 4d; INK4D; p19; p19-INK4D

Molecular Weight

Mass (kDA):
17.7 kDA

Genomic Context

Human
Location:	19p13.2
Sequence:	19; NC_000019.10 (10566460..10568979, complement)

Subcellular Localizations

Nucleus. Cytoplasm.

Diseases

• Neoplasms
• Malignant Neoplasms
• Retinoblastoma
• Leukemia
• Carcinoma
• Cell Transformation, Neoplastic
• Growth Arrest
• Myeloid Leukemia
• Nervousness
• Acute Lymphocytic Leukemia
• Malignant Paraganglionic Neoplasm
• Carcinogenesis
• Testicular Neoplasms

• Ovarian Neoplasm
• Leukemia, Myelocytic, Acute
• Hyperplasia
• Melanoma
• Malignant Neoplasm Of Ovary
• Cytogenetic Abnormality
• Malignant Squamous Cell Neoplasm

Interacting Proteins

• C1orf94
• CDK4
• CDK6
• HSD17B14
• IKZF3

• INCA1
• NR4A1

Pathways

• Cell Cycle
• Cell Proliferation
• Cell Division
• G1 Phase
• Pathogenesis
• Cell Differentiation
• S Phase
• Senescence
• Cell Growth
• Methylation
• Spermatogenesis
• Dna Replication
• Dna Repair

• Dna Methylation
• Cell Cycle Arrest
• Cell Death
• Oncogenesis
• Cellular Senescence
• Neurogenesis
• Meiosis

PTMs

• Phosphorylation
• Methylation
• Demethylation

• Cleavage
• Deacetylation
• Dephosphorylation

• Ubiquitination

Research Areas

• Cell Cycle and Replication
• Ovarian Carcinoma Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CDKN2D

Best Uses of the CDKN2D Marker

The CDKN2D marker has numerous applications in research. It is used to create custom genome edited models of zebrafish and c. elegans. In this article, we will discuss Boster Bio and its CDKN2A genome editing models, and describe their applications. If you are an educator, you may use Boster Bio's educational resources for your classroom, but please be sure to cite and link to Boster Bio.

Boster Bio

CDKN2D is a protein that is expressed in cells. It has important functions in cell cycle regulation and differentiation, as well as in coupling these two processes. The best uses of the CDKN2D gene are outlined below. Let's take a look at how it can be used in biology research. In addition to its role in cell cycle regulation, it also plays an important role in regulating NB4 differentiation.

InVivo Biosystems

The CDKN2D marker is a gene related to cyclin D1, a protein that is essential for cell division. The CDKN2D gene is a regulatory element that is mutated in many cancers. The CDKN2D gene is responsible for regulating the activity of cyclin D1. The protein functions in cell division and is essential for the maintenance of normal cellular function.

InVivo Biosystems Custom zebrafish/c. elegans genome edited models for CDKN2A

For studies that focus on human cancer, InVivo Biosystems has developed genome-edited models of CDKN2A. These models are available for purchase for $3250. CDKN2A is a member of the family of cyclin-dependent kinases. Its role in cancer is not fully understood, but it is believed to contribute to the development of certain types of tumors.

These custom-built models can be used to study the role of CDKN2A in cancer. The targeted sequence can be part of an infectious agent, human immunodeficiency virus, or cancer-related gene. Alternatively, it could be a protein involved in immune suppression. In the latter case, the InVivo Biosystems Custom zebrafish/c. elegans genome-edited models will be used to determine whether the targeted molecule is active in cancer cells.

Using an ex-vivo nucleic acid editing system, gRNA, or RNA conjugate material, researchers can study the effect of a given drug on CDKN2A. They may be injected into the cell or applied directly to the target tissues. Monitoring of the nucleic acid modification over time may involve periodic biopsy, PCR amplification of the corrected gene, or expression of a reporter gene or its corrected gene product.

The company uses a Cas9-guided DNA nuclease to create human-friendly genome-edited models. It is a process known as CRISPR-Cas system. Sander and Joung describe the technology. The company has also produced human-compatible Cas9-mRNA systems.

Cas9-guided DNA editing in zebrafish/c. elegans genome-edited models are a convenient tool for studying gene function. Cas9-guided CRISPR-Cas9 gene-editing system disrupts coding sequences or integral regulatory domains of a gene. As a result, the gene is deleted or altered in a specific phenotype.

This custom-made nucleic acid editing system produces a modified gene in the target cell. This system is expressed in the target cell for two to four weeks. The editing system delivers a specific nucleic acid to the target cell. The RNA-encoding RNA encoding system also expresses a sgRNA (short for single-stand DNA) that targets a FAH mutation.

Applications of the CDKN2D Marker

While it is still unclear how CDKN2D functions in cancer, the expression level of this gene has been studied in several studies. In the present study, we show that CDKN2D expression in brain tissue was associated with the development of neurofibrillary tangles. Although this marker has limited applications, it will help researchers understand how it works. The next step is to study its potential role in Alzheimer's disease.

The CDKN2D gene is regulated by the protein MAP3K1. Its expression inhibits apoptosis and cell division. When overexpressed, the gene inhibits EC9706 cell growth. In addition, CDKN2D has been shown to be a transcriptional co-regulator of miR-451. For this reason, it is important to understand how the CDKN2D gene works and how it is targeted by miRNAs.